The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double‐blind, placebo‐controlled study
Abstract
Based on several open‐label and case studies, repetitive transcranial magnetic stimulation (rTMS) seems to have an antidepressive effect on patients with Parkinson's disease (PD). However, this hypothesis requires further confirmation. We conducted a randomized, double‐blind placebo‐controlled study to evaluate the effect of rTMS over the left dorsolateral prefrontal cortex (DLPFC) on depression and various motor and nonmotor features of PD. Twenty‐two PD patients with mild or moderate depressive episodes were assigned into two groups, one receiving real‐rTMS (90% of resting motor threshold, 5 Hz, 600 pulses‐a‐day for 10 days) over the left DLPFC, and another group receiving sham‐rTMS. An investigator blinded to the treatment performed three video‐taped examinations on each patient: before stimulation (baseline), 1 day (short term), and 30 days after treatment session ended (long‐term effect). Mini‐Mental State Examination, Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn‐Yahr, Epworth Sleepiness, Visual Analog and Montgomery‐Asberg Depression Rating Scales (MADRS), Beck Depression Inventory (BDI), and Trail making and Stroop tests were applied. In the actively treated group, not only depression rating scales showed significant improvement 30 days after treatment ended (BDI by 44.4% and MADRS by 26.1%), but also the accuracy of Stroop test (by 16%). We could also demonstrate an insignificant improvement in UPDRS‐III by 7.5 points (31.9%, P = 0.06). In the sham‐treated group none of the examined tests and scales improved significantly after sham stimulation. Our study demonstrated the beneficial effect of the left DLPFC rTMS on depression in PD lasting at least 30 days after treatment. However, this result should be confirmed in patients with severe depression by further clinical trials. © 2010 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons
Podsiadlo, D., & Richardson, S. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb01616.x · Cited by 14,418
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
de Boer, A. G. E. M., van Lanschot, J. J. B., Stalmeier, P. F. M., van Sandick, J. W., Hulscher, J. B. F., de Haes, J. C. J. M., & Sprangers, M. A. G. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018499.64574.1f · Cited by 743
Boggio, P. S., Fregni, F., Bermpohl, F., Mansur, C. G., Rosa, M., Rumi, D. O., Barbosa, E. R., Odebrecht Rosa, M., Pascual‐Leone, A., Rigonatti, S. P., et al. (2005) · Movement Disorders · doi:10.1002/mds.20508 · Cited by 216
Cited by
Lefaucheur, J.-P., Aleman, A., Baeken, C., Benninger, D. H., Brunelin, J., Di Lazzaro, V., Filipović, S. R., Grefkes, C., Hasan, A., Hummel, F. C., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.11.002 · Cited by 2,382
Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., et al. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.05.021 · Cited by 2,119
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Fox, M. D., Buckner, R. L., Liu, H., Chakravarty, M. M., Lozano, A. M., & Pascual-Leone, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405003111 · Cited by 617
Depression in Parkinson disease—epidemiology, mechanisms and management
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.189 · Cited by 593
Parkinson's disease: The quintessential neuropsychiatric disorder
Weintraub, D., & Burn, D. J. (2011) · Movement Disorders · doi:10.1002/mds.23664 · Cited by 423
Depression and Parkinson’s Disease: Current Knowledge
Marsh, L. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0409-5 · Cited by 404
Begemann, M. J., Brand, B. A., Ćurčić-Blake, B., Aleman, A., & Sommer, I. E. (2020) · Psychological Medicine · doi:10.1017/s0033291720003670 · Cited by 368
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Psychosis, apathy, depression and anxiety in Parkinson's disease
Gallagher, D. A., & Schrag, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.041 · Cited by 211
Martin, D. M., McClintock, S. M., Forster, J. J., Lo, T. Y., & Loo, C. K. (2017) · Depression and Anxiety · doi:10.1002/da.22658 · Cited by 162
Troeung, L., Egan, S. J., & Gasson, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079510 · Cited by 132
“These were; citalopram and desipramine [17], nortriptyline [19], paroxetine and venlafaxine [20], Omega-3 supplementation [43], and CBT [55].”
BackgroundInfluentialMartin, D. M., McClintock, S. M., Forster, J., & Loo, C. K. (2016) · Neuropsychology Review · doi:10.1007/s11065-016-9325-1 · Cited by 76
Optimal Treatment of Depression and Anxiety in Parkinson's Disease
Pontone, G. M., & Mills, K. A. (2021) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.02.037 · Cited by 67
Metadata
- Authors
- Pal, E., Nagy, F., Aschermann, Z., Balazs, E., & Kovacs, N.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2010-08-24
- Volume
- 25
- Issue
- 14
- Pages
- 2311-2317
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2045004405
- Cited by
- 199
- References
- 4
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.